Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model

Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model

Abstract Although triple-negative breast cancers are still challenging to treat, the development of novel neoadjuvant chemotherapy combined with immune checkpoint antibodies is promising. Our group developed the small compound-based anti-PD-1/PD-L1 inhibitor SCL-1 and reported its potent anti-tumor...

Full description

Saved in:
Bibliographic Details
Main Authors: Tomoatsu Ikeya, Tadashi Ashizawa, Akari Kanematsu, Chie Maeda, Akira Iizuka, Kazue Yamashita, Haruo Miyata, Yasufumi Kikuchi, Kouji Maruyama, Mamoru Ito, Ken Yamaguchi, Yasuto Akiyama
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Immune checkpoint inhibitor
PD-1/PD-L1
Triple-negative breast cancer
NOG mouse
Humanized mouse
Online Access:https://doi.org/10.1038/s41598-025-12103-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-12103-6

Similar Items